Brii Biosciences Limited
BRIBF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $50 | $1 | $52 | $93 |
| % Growth | 7,993.4% | -98.8% | -44.2% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $50 | $1 | $52 | $93 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $250 | $403 | $441 | $495 |
| G&A Expenses | $153 | $56 | $53 | $79 |
| SG&A Expenses | $204 | $57 | $80 | $79 |
| Sales & Mktg Exp. | $51 | $1 | $27 | $0 |
| Other Operating Expenses | $0 | $86 | $45 | $129 |
| Operating Expenses | $454 | $545 | $566 | $703 |
| Operating Income | -$404 | -$544 | -$514 | -$610 |
| % Margin | -808.7% | -88,217.3% | -995.3% | -659.7% |
| Other Income/Exp. Net | -$109 | $360 | $24 | -$3,581 |
| Pre-Tax Income | -$512 | -$184 | -$490 | -$4,191 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$508 | -$175 | -$484 | -$4,120 |
| % Margin | -1,017.6% | -28,335.3% | -938.1% | -4,452.3% |
| EPS | -0.7 | -0.24 | -0.67 | -9.48 |
| % Growth | -191.7% | 64.2% | 92.9% | – |
| EPS Diluted | -0.7 | -0.24 | -0.67 | -9.48 |
| Weighted Avg Shares Out | 730 | 728 | 723 | 439 |
| Weighted Avg Shares Out Dil | 730 | 728 | 723 | 439 |
| Supplemental Information | – | – | – | – |
| Interest Income | $85 | $108 | $37 | $6 |
| Interest Expense | $0 | $0 | $1 | $1 |
| Depreciation & Amortization | $2 | $16 | $8 | $8 |
| EBITDA | -$402 | -$168 | -$504 | -$603 |
| % Margin | -804.2% | -27,261.3% | -975.4% | -651.4% |